Figure 6.

The senescence inhibitor, rapamycin, antagonizes IGFBP7 reprogramming in fibroblast. Fibroblasts were treated with IGFBP7 (1000 ng/mL) alone or in combination with rapamycin (500 μM) and gene expression was measured by qPCR. Rapamycin decreased expression of senescence‐associated genes (P16, P21, and P53; A‐C), SASP‐associated genes (IL‐1α, TNF‐α, and IL‐6; D‐F) and osteogenic genes (Runx2, BMP‐2, bone sialoprotein, and osteocalcin; G‐J). Matrix mineralization and bone nodules formation were also impaired in cells treated with rapamycin (K). *P ≤ .05 when comparing to IGFBP7 treatment only at day 14 using a Student's t test. Data were replicated in four independent experiments